Company Information
- Type:
- Company
- Country:
- United States of America
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 28 April 2017 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Financial Information
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 29-Jul-2024 | 2024 Communication on Progress | Submitted |
| 28-Apr-2022 | 2021 Communication on Progress | Active |
| 18-May-2021 | Communication on Progress | Active |
| 19-May-2020 | Amgen 2019 Communication on Progress | Active |
| 20-May-2019 | 2018 Communication on Progress | Active |
| 22-May-2018 | Amgen 2017 Communication on Progress | Active |
| 09-Jan-2018 | Reporting Cycle Adjustment | Not applicable |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP , for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.